Alliance for Aging Research AD Biomarkers Work Group: Structural MRI

Neurobiology of Aging

Volumn 32, Issue SUPPL. 1, 2011, Pages

  Jack, Clifford R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Biomarkers; MRI

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID DEPOSITION; AUTOMATION; AUTOPSY; BIOACCUMULATION; BRAIN ATROPHY; BRAIN HEMORRHAGE; BRAIN SIZE; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGING SYSTEM; MEMORY; MILD COGNITIVE IMPAIRMENT; MORPHOMETRICS; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; TEMPORAL LOBE; TENSOR BASED MORPHOMETRY; THREE DIMENSIONAL IMAGING; VOXEL BASED MORPHOMETRY;

EID: 80955166403     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.09.011     Document Type: Article

References (84)

1. Alexander G.E., Moeller J.R. Application of the scaled subprofile model to functional imaging in neuropsychiatric disorders: a principal component approach to modeling regional patterns of brain function in disease. Hum. Brain Mapp. 1994, 2:79-94.
2. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
3. Bakkour A., Morris J.C., Dickerson B.C. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009, 72:1048-1055.
4. Bobinski M., de Leon M.J., Wegiel J., Desanti S., Convit A., Saint Louis L.A., Rusinek H., Wisniewski H.M. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000, 95:721-725.
5. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
6. Brys M., Glodzik L., Mosconi L., Switalski R., De Santi S., Pirraglia E., Rich K., Kim B.C., Mehta P., Zinkowski R., Pratico D., Wallin A., Zetterberg H., Tsui W.H., Rusinek H., Blennow K., de Leon M.J. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J. Alzheimers Dis 2009, 16:351-362.
7. Chételat G., Landeau B., Eustache F., Mézenge F., Viader F., de la Sayette V., Desgranges B., Baron J.C. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 2005, 27:934-946.
8. Convit A., de Asis J., de Leon M.J., Tarshish C.Y., De Santi S., Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol. Aging 2000, 21:19-26.
9. Csernansky J.G., Hamstra J., Wang L., McKeel D., Price J.L., Gado M., Morris J.C. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis. Assoc. Disord 2004, 18:190-195.
10. Csernansky J.G., Wang L., Joshi S., Miller J.P., Gado M., Kido D., McKeel D., Morris J.C., Miller M.I. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type. Neurology 2000, 55:1636-1643.
11. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999, 9:179-194.
12. Davatzikos C., Xu F., An Y., Fan Y., Resnick S.M. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain 2009, 132:2026-2035.
13. DeCarli C., Frisoni G.B., Clark C.M., Harvey D., Grundman M., Petersen R.C., Thal L.J., Jin S., Jack C.R., Scheltens P. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch. Neurol 2007, 64:108-115. Alzheimer's Disease Cooperative Study Group.
14. Desikan R.S., Cabral H.J., Hess C.P., Dillon W.P., Glastonbury C.M., Weiner M.W., Schmansky N.J., Greve D.N., Salat D.H., Buckner R.L., Fischl B. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 2009, 132:2048-2057.
15. Desikan R.S., Fischl B., Cabral H.J., Kemper T.L., Guttmann C.R., Blacker D., Hyman B.T., Albert M.S., Killiany R.J. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal. Adv. Neurol 2008, 71:819-825.
16. Devanand D.P., Pradhaban G., Liu X., Khandji A., De Santi S., Segal S., Rusinek H., Pelton G.H., Honig L.S., Mayeux R., Stern Y., Tabert M.H., de Leon M.J. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007, 68:828-836.
17. Eckerström C., Olsson E., Borga M., Ekholm S., Ribbelin S., Rolstad S., Starck G., Edman A., Wallin A., Malmgren H. Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: the Göteborg MCI study. J. Neurol. Sci 2008, 272:48-59.
18. Fan Y., Shen D., Davatzikos C. Classification of structural images via high-dimensional image warping, robust feature extraction, and SVM. Med. Image Comput. Comput. Assist. Interv. 2005, 8:1-8.
19. Fischer P., Jungwirth S., Zehetmayer S., Weissgram S., Hoenigschnabl S., Gelpi E., Krampla W., Tragl K.H. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007, 68:288-291.
20. Fischl B., van der Kouwe A., Destrieux C., Halgren E., Ségonne F., Salat D.H., Busa E., Seidman L.J., Goldstein J., Kennedy D., Caviness V., Makris N., Rosen B., Dale A.M. Automatically parcellating the human cerebral cortex. Cereb. Cortex 2004, 14:11-22.
21. Fleisher A.S., Sun S., Taylor C., Ward C.P., Gamst A.C., Petersen R.C., Jack C.R., Aisen P.S., Thal L.J. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 2008, 70:191-199.
22. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572. AN1792(QS-21)-201 Study Team.
23. Fox N.C., Cousens S., Scahill R., Harvey R.J., Rossor M.N. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch. Neurol. 2000, 57:339-344.
24. Fox N.C., Freeborough P.A. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J. Magn. Reson. Imaging 1997, 7:1069-1075.
25. Fox N.C., Freeborough P.A., Rossor M.N. Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet 1996, 348:94-97.
26. Freeborough P.A., Fox N.C. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans. Med. Imaging 1997, 16:623-629.
27. Galluzzi S., Geroldi C., Ghidoni R., Paghera B., Amicucci G., Bonetti M., Zanetti O., Cotelli M., Gennarelli M., Frisoni G.B. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J. Neurol 2010, 257:2004-2014. Translational Outpatient Memory Clinic Working Group.
28. Galton C.J., Erzinçlioglu S., Sahakian B.J., Antoun N., Hodges J.R. A comparison of the Addenbrooke's Cognitive Examination (ACE), conventional neuropsychological assessment, and simple MRI-based medial temporal lobe evaluation in the early diagnosis of Alzheimer's disease. Cogn. Behav. Neurol 2005, 18:144-150.
29. Gerardin E., Chételat G., Chupin M., Cuingnet R., Desgranges B., Kim H.S., Niethammer M., Dubois B., Lehéricy S., Garnero L., Eustache F., Colliot O. Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage 2009, 47:1476-1486. Alzheimer's Disease Neuroimaging Initiative.
30. Gosche K.M., Mortimer J.A., Smith C.D., Markesbery W.R., Snowdon D.A. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002, 58:1476-1482.
31. Hashimoto M., Kazui H., Matsumoto K., Nakano Y., Yasuda M., Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am. J. Psychiatry 2005, 162:676-682.
32. Henneman W.J., Sluimer J.D., Barnes J., van der Flier W.M., Sluimer I.C., Fox N.C., Scheltens P., Vrenken H., Barkhof F. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009, 72:999-1007.
33. Herukka S.K., Pennanen C., Soininen H., Pirttilä T. CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J. Alzheimers Dis 2008, 14:51-57.
34. Hinrichs C., Singh V., Mukherjee L., Xu G., Chung M.K., Johnson S.C. Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. Neuroimage 2009, 48:138-149. Alzheimer's Disease Neuroimaging Initiative.
35. Holland D., Brewer J.B., Hagler D.J., Fennema-Notestine C., Dale A.M. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20954-20959. Alzheimer's Disease Neuroimaging Initiative.
36. Hua X., Hibar D.P., Lee S., Toga A.W., Jack C.R., Weiner M.W., Thompson P.M. Sex and age differences in brain atrophic rates: an ADNI study with N=1368 MRI scans. Neurobiol. Aging 2010, 31:1463-1480.
37. Hua X., Leow A.D., Lee S., Klunder A.D., Toga A.W., Lepore N., Chou Y.Y., Brun C., Chiang M.C., Barysheva M., Jack C.R., Bernstein M.A., Britson P.J., Ward C.P., Whitwell J.L., Borowski B., Fleisher A.S., Fox N.C., Boyes R.G., Barnes J., Harvey D., Kornak J., Schuff N., Boreta L., Alexander G.E., Weiner M.W., Thompson P.M. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. NeuroImage 2008, 41:19-34. Alzheimer's Disease Neuroimaging Initiative.
38. Jack C.R., Dickson D.W., Parisi J.E., Xu Y.C., Cha R.H., O'Brien P.C., Edland S.D., Smith G.E., Boeve B.F., Tangalos E.G., Kokmen E., Petersen R.C. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58:750-757.
39. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
40. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
41. Jack C.R., Petersen R.C., Grundman M., Jin S., Gamst A., Ward C.P., Sencakova D., Doody R.S., Thal L.J. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol. Aging 2008, 29:1285-1295. Members of the Alzheimer's Disease Cooperative Study (ADCS).
42. Jack C.R., Petersen R.C., O'Brien P.C., Tangalos E.G. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992, 42:183-188.
43. Jack C.R., Petersen R.C., Xu Y., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Tangalos E.G., Kokmen E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000, 55:484-489.
44. Jack C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Waring S.C., Tangalos E.G., Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397-1403.
45. Jack C.R., Shiung M.M., Weigand S.D., O'Brien P.C., Gunter J.L., Boeve B.F., Knopman D.S., Smith G.E., Ivnik R.J., Tangalos E.G., Petersen R.C. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65:1227-1231.
46. Jack C.R., Slomkowski M., Gracon S., Hoover T.M., Felmlee J.P., Stewart K., Xu Y., Shiung M., O'Brien P.C., Cha R., Knopman D., Petersen R.C. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003, 60:253-260.
47. Jack C.R., Wiste H.J., Vemuri P., Weigand S.D., Senjem M.L., Zeng G., Bernstein M.A., Gunter J.L., Pankratz V.S., Aisen P.S., Weiner M.W., Petersen R.C., Shaw L.M., Trojanowski J.Q., Knopman D.S. Brain beta-amyloid measure and magnetic resonance imaging atophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010, 133:3336-3348.
48. Jagust W.J., Zheng L., Harvey D.J., Mack W.J., Vinters H.V., Weiner M.W., Ellis W.G., Zarow C., Mungas D., Reed B.R., Kramer J.H., Schuff N., DeCarli C., Chui H.C. Neuropathological basis of magnetic resonance images in aging and dementia. Ann. Neurol 2008, 63:72-80.
49. Kantarci K., Petersen R.C., Boeve B.F., Knopman D.S., Weigand S.D., O'Brien P.C., Shiung M.M., Smith G.E., Ivnik R.J., Tangalos E.G., Jack C.R. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2005, 64:902-904.
50. Killiany R.J., Gomez-Isla T., Moss M., Kikinis R., Sandor T., Jolesz F., Tanzi R., Jones K., Hyman B.T., Albert M.S. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann. Neurol 2000, 47:430-439.
51. Killiany R.J., Hyman B.T., Gomez-Isla T., Moss M.B., Kikinis R., Jolesz F., Tanzi R., Jones K., Albert M.S. MRI measures of entorhinal cortex vs hippocampus in preclinical. Adv. Neurol 2002, 58:1188-1196.
52. Kloppel S., Stonnington C.M., Chu C., Draganski B., Scahill R.I., Rohrer J.D., Fox N.C., Jack C.R., Ashburner J., Frackowiak R.S. Automatic classification of MR scans in Alzheimer's disease. Brain 2008, 131:681-689.
53. Kohannim O., Hua X., Hibar D.P., Lee S., Chou Y.-Y., Toga A.W., Jack C.R., Weiner M.W., Thompson P.M. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol. Aging 2010, 31:1429-1442.
54. Krishnan K.R., Charles H.C., Doraiswamy P.M., Mintzer J., Weisler R., Yu X., Perdomo C., Ieni J.R., Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am. J. Psychiatry 2003, 160:2003-2011.
55. Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Petersen R.C., Shaw L.M., Trojanowski J.Q., Jack C.R., Weiner M.W., Jagust W.J. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238. Alzheimer's Disease Neuroimaging Initiative.
56. Leung K.K., Clarkson M.J., Bartlett J.W., Clegg S., Jack C.R., Weiner M.W., Fox N.C., Ourselin S. Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection. Neuroimage 2010, 50:516-523. Alzheimer's Disease Neuroimaging Initiative.
57. McEvoy L.K., Fennema-Notestine C., Roddey J.C., Hagler D.J., Holland D., Karow D.S., Pung C.J., Brewer J.B., Dale A.M. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 2009, 251:195-205. Alzheimer's Disease Neuroimaging Initiative.
58. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med 2004, 256:183-194.
59. Petersen R.C. Mild cognitive impairment. Continuum lifelong learning. Neurologist 2007, 13:15-38.
60. Risacher S.L., Saykin A.J., West J.D., Shen L., Firpi H.A., McDonald B.C. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr. Alzheimer Res 2009, 6:347-361. Alzheimer's Disease Neuroimaging Initiative (A.D.N.I.).
61. Scheltens P., Leys D., Barkhof F., Huglo D., Weinstein H.C., Vermersch P., Kuiper M., Steinling M., Wolters E.C., Valk J. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J. Neurol. Neurosurg. Psychiatry 1992, 55:967-972.
62. Schott J.M., Frost C., Whitwell J.L., Macmanus D.G., Boyes R.G., Rossor M.N., Fox N.C. Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials. J. Neurol. 2006, 253:1147-1153.
63. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., Thompson P.M., Jack C.R., Weiner M.W. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009, 132:1067-1077.
64. Silbert L.C., Quinn J.F., Moore M.M., Corbridge E., Ball M.J., Murdoch G., Sexton G., Kaye J.A. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003, 61:487-492.
65. Stonnington C.M., Tan G., Klöppel S., Chu C., Draganski B., Jack C.R., Chen K., Ashburner J., Frackowiak R.S. Interpreting scan data acquired from multiple scanners: a study with Alzheimer's disease. Neuroimage 2008, 39:1180-1185.
66. Stoub T.R., Rogalski E.J., Leurgans S., Bennett D.A., deToledo-Morrell L. Rate of entorhinal and hippocampal atrophy in incipient and mild AD: relation to memory function. Neurobiol. Aging 2010, 31:1089-1098.
67. Tapiola T., Pennanen C., Tapiola M., Tervo S., Kivipelto M., Hänninen T., Pihlajamäki M., Laakso M.P., Hallikainen M., Hämäläinen A., Vanhanen M., Helkala E.L., Vanninen R., Nissinen A., Rossi R., Frisoni G.B., Soininen H. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Neurobiol. Aging 2008, 29:31-38.
68. Thompson P.M., Apostolova L.G. Computational anatomical methods as applied to ageing and dementia. Br. J. Radiol 2007, 80(SPEC 2):S78-S91.
69. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
70. Vemuri P., Gunter J.L., Senjem M.L., Whitwell J.L., Kantarci K., Knopman D.S., Boeve B.F., Petersen R.C., Jack C.R. Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008, 39:1186-1197.
71. Vemuri P., Jack C.R. Role of structural MRI in Alzheimer's disease. Alzheimers Res. Ther 2010, 2:23.
72. Vemuri P., Whitwell J.L., Kantarci K., Josephs K.A., Parisi J.E., Shiung M.S., Knopman D.S., Boeve B.F., Petersen R.C., Dickson D.W., Jack C.R. Ante mortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008, 42:559-567.
73. Vemuri P., Wiste H.J., Weigand S.D., Knopman D.S., Trojanowski J.Q., Shaw L.M., Bernstein M.A., Aisen P.S., Weiner M., Petersen R.C., Jack C.R. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 2010, 75:143-151. Alzheimer's Disease Neuroimaging Initiative, D.N.
74. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 2009, 73:294-301. Alzheimer's Disease Neuroimaging Initiative.
75. Visser P.J., Krabbendam L., Verhey F.R., Hofman P.A., Verhoeven W.M., Tuinier S., Wester A., Den Berg Y.W., Goessens L.F., Werf Y.D., Jolles J. Brain correlates of memory dysfunction in alcoholic Korsakoff's syndrome. J. Neurol. Neurosurg., Psychiatry 1999, 67:774-778.
76. Visser P.J., Verhey F.R., Hofman P.A., Scheltens P., Jolles J. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J. Neurol. Neurosurg. Psychiatry 2002, 72:491-497.
77. Walhovd K.B., Fjell A.M., Brewer J., McEvoy L.K., Fennema-Notestine C., Hagler D.J., Jennings R.G., Karow D., Dale A.M. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am. J. Neuroradiol 2010, 31:347-354. Alzheimer's Disease Neuroimaging Initiative.
78. Wang P.N., Liu H.C., Lirng J.F., Lin K.N., Wu Z.A. Accelerated hippocampal atrophy rates in stable and progressive amnestic mild cognitive impairment. Psychiatry Res 2009, 171:221-231.
79. Welch E.B., Manduca A., Grimm R.C., Ward H.A., Jack C.R. Spherical navigator echoes for full 3-D rigid body motion measurement in MRI. Mag Reson Med 2002, 47(1):32-41.
80. Whitwell J.L., Josephs K.A., Murray M.E., Kantarci K., Przybelski S.A., Weigand S.D., Vemuri P., Senjem M.L., Parisi J.E., Knopman D.S., Boeve B.F., Petersen R.C., Dickson D.W., Jack C.R. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008, 71:743-749.
81. Whitwell J.L., Przybelski S.A., Weigand S.D., Knopman D.S., Boeve B.F., Petersen R.C., Jack C.R. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007, 130:1777-1786.
82. Wolz R., Heckemann R.A., Aljabar P., Hajnal J.V., Hammers A., Lötjönen J., Rueckert D. Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI. Neuroimage 2010, 52:109-118. Alzheimer's Disease Neuroimaging Initiative.
83. Xu Y., Jack C.R., O'Brien P.C., Kokmen E., Smith G.E., Ivnik R.J., Boeve B.F., Tangalos R.G., Petersen R.C. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 2000, 54:1760-1767.
84. Zarow C., Vinters H.V., Ellis W.G., Weiner M.W., Mungas D., White L., Chui H.C. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann. Neurol 2005, 57:896-903.